argenex SE $ARGX Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lowered its position in shares of argenex SE (NASDAQ:ARGX) by 11.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 9,027 shares of the company’s stock after selling 1,168 shares during the period. Crossmark Global Holdings Inc.’s holdings in argenex were worth $6,658,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Bessemer Group Inc. lifted its position in argenex by 276.5% in the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after purchasing an additional 47 shares during the last quarter. Mather Group LLC. bought a new position in argenex in the 3rd quarter worth about $50,000. Rossby Financial LCC grew its position in argenex by 115.2% in the 3rd quarter. Rossby Financial LCC now owns 71 shares of the company’s stock worth $54,000 after purchasing an additional 38 shares during the last quarter. TD Private Client Wealth LLC increased its stake in shares of argenex by 750.0% in the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after purchasing an additional 75 shares during the period. Finally, MAI Capital Management increased its stake in shares of argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after purchasing an additional 78 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Trading Down 1.4%

Shares of ARGX opened at $717.80 on Friday. The business’s 50-day moving average price is $815.53 and its 200 day moving average price is $813.87. The stock has a market capitalization of $44.42 billion, a P/E ratio of 36.77, a P/E/G ratio of 1.19 and a beta of 0.38. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 26th. The company reported $8.02 EPS for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 38.51%. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. On average, research analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

ARGX has been the subject of several analyst reports. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. HC Wainwright raised their target price on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research report on Friday, February 27th. DZ Bank raised argenex to a “strong-buy” rating in a research note on Friday, December 19th. Citigroup reduced their price target on argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Finally, Morgan Stanley increased their price target on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $999.22.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.